The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | Current and future implications of MRD in myeloma
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the current and future implications of measurable residual disease (MRD) in multiple myeloma. Dr Costa first highlights the importance of MRD as a powerful prognostic tool, and further discusses how it can be used to identify patients at high risk of relapse. Following this, Dr Costa discusses some ongoing and future clinical trials incorporating MRD, including the AURIGA trial (NCT03901963), the MIDAS trial (NCT04934475), and the upcoming MASTER-2 trial (NCT05231629). This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Disclosures
Research support: Amgen, Janssen, BMS, AbbVie, Ionis, Genentech
Honorarium: Amgen, Janssen, Sanofi, Karyopharm, BMS, Astra Zeneca, Adaptive Biotechnologies, Takeda, Pfizer
